ascopubs.org

Risk of pre-cancerous advanced adenomas of the colon in long distance runners.

The impact of dietary patterns on inflammation and colon cancer risk: A retrospective study of 796 patients.
ascopubs.org

Use of artificial intelligence–assistance software for HER2-low and HER2-ultralow IHC interpretation training to improve diagnostic accuracy of pathologists and expand ...

Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor–positive (HR+) metastatic breast cancer (mBC) in ...
ascopubs.org

Impact of a novel oral medication delivery device on patient engagement and discontinuation in individuals receiving oral oncolytic medications.

Trends and disparities in sepsis-related mortality among patients with malignancies: A 25-year nationwide analysis. Discontinuation at 3, 6, and 12 months and reason for discontinuation.
ascopubs.org

Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.

Plasma-guided adaptive first-line chemoimmunotherapy for non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full ...
ascopubs.org

Low-dose aspirin to reduce recurrence rate in colorectal cancer patients with PI3K pathway alterations: 3-year results from a randomized placebo-controlled trial.

A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC ...
ascopubs.org

Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer.

Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, ...
ascopubs.org

Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial.

Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting II. This abstract does not ...
ascopubs.org

Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.

Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting II.
ascopubs.org

Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.

A phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors. This is an ASCO Meeting Abstract from ...
ascopubs.org

Using an artificial intelligence platform to enhance cancer detection rates in primary care.

Performance of an artificial intelligence/machine learning model designed to identify hospitalized patients with cancer who could benefit from timely specialized palliative care delivery. This is an ...
ascopubs.org

Impact of urolithin A supplementation, a mitophagy activator on mitochondrial health of immune cells (MitoIMMUNE): A randomized, double-blind, placebo-controlled trial in ...

The effect of resting dendritic cells on overall survival in the hepatocellular carcinoma tumor microenvironment. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
ascopubs.org

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).

Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 ...